Clinical trials: B-cell Malignancy
Refractory/Recurrent Central Nervous System Lymphoma
Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System Lymphoma
This study is designed to evaluate the safety and efficacy of cord blood-derived CAR-NK019 in the treatment of refractory/relapsed central nervous system lymphoma.
- Trial name
- NCT06827782
- Testing
- anti-CD19 CAR-NK cells
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Follicular Lymphoma, Refractory B-Cell Lymphoma
Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma
To observe the safety and efficacy of Chidamide combined with Linperlisib in the treatment of refractory and relapsed follicular lymphoma.
- Conditions
- Follicular Lymphoma, Refractory B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
- Trial name
- NCT06158386
- Testing
- Chidamide combined with Linperlisib
- Where
- China
- Volunteers
- 33 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Chronic Lymphocytic Leukemia
Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)
A prospective, open-label, multicentre phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by ofatumumab and ibrutinib followed by ibrutinib and ofatumumab maintenance in CLL…
- Trial name
- NCT02689141
- Testing
- Bendamustine, Ofatumumab, Ibrutinib
- Where
- Germany
- Volunteers
- 66 people
- Sponsor
- German CLL Study Group
Hematologic Neoplasms
A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies
The primary objective of this study is to characterize the safety, tolerability, dose-limiting toxicities (DLTs), and maximum tolerated dose (MTD) of relatlimab administered alone or in combination with nivolumab to subjects with…
- Trial name
- NCT02061761
- Testing
- BMS-986016, BMS-936558
- Where
- 10 sites in United States, Canada
- Volunteers
- 106 people
- Sponsor
- Bristol-Myers Squibb
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
This phase I trial studies the safety and how effective the combination of ublituximab, umbralisib, and lenalidomide is in certain types of indolent (slow-growing) non-Hodgkin's lymphoma or mantle cell lymphoma.
- Conditions
- Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma
- Trial name
- NCT04635683
- Testing
- Lenalidomide, Ublituximab, Umbralisib
- Sponsor
- Yazeed Sawalha
Leukemia, Lymphoma
Rituximab in Treating Young Patients Who Are Receiving Chemotherapy for B-Cell Non-Hodgkin's Lymphoma or B-Cell Acute Lymphoblastic Leukemia
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them.
- Trial name
- NCT00324779
- Testing
- rituximab
- Where
- 38 sites in Germany, Switzerland
- Volunteers
- 79 people
- Sponsor
- University Hospital Erlangen
Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma
First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies
NVG-111 is a bispecific antibody drug, having two "arms", one arm attaches to a substance on cancer cells called ROR1, the other arm attaches to the body's immune cells directing them to kill the cancer cells.
- Conditions
- Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
- Trial name
- NCT04763083
- Testing
- NVG-111
- Where
- 3 sites in United Kingdom
- Volunteers
- 90 people
- Sponsor
- NovalGen Ltd.
Relapsed or Refractory B-cell Lymphoma
Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma
PD1 pathway is critical in determining the response to CAR T cell therapy. Emerging data suggested that Inhibition of PD1 could enhance the efficacy of CAR T cell therapy.
- Trial name
- NCT03208556
- Testing
- iPD1 CD19 eCAR T cells, Fludarabine and cyclophosphamide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking University
Diffuse Large B Cell Lymphoma
A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL Patients
The primary objective of the study is to assess the efficiency of SCT400 plus CHOP versus Rituximab plus CHOP in untreated CD20-positive DLBCL Patients.
- Trial name
- NCT02772822
- Testing
- SCT400 plus CHOP, Rituximab plus CHOP
- Where
- China
- Volunteers
- 330 people
- Sponsor
- Sinocelltech Ltd.
Chronic Lymphoid Leukemia
The Effect of 25-OH-Vitamin-D3 Substitution in Patients With Malignant and Immune-hematologic Diseases
Recent data have shown that the inadequate vitamin D status plays a role in the manifestation of the haematologic tumors and serum vitamin D level has a prognostic role also as it determines the tumor mortality.
- Trial name
- D-HEM (NCT01518959)
- Testing
- Cholecalciferol, oleum neutralicum
- Where
- Hungary
- Volunteers
- 31 people
- Sponsor
- Semmelweis University
Marginal Zone Lymphoma
Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)
The purpose of this clinical trial is to learn if the drugs Pirtobrutinib and Rituximab are effective for the treatment of newly diagnosed marginal zone lymphoma.
- Trial name
- NCT06390956
- Testing
- Pirtobrutinib, Rituximab
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- University of Utah
Leukemia, Lymphocytic, Chronic, B-Cell
Institut Paoli Calmettes Chronic Lymphatic Leukemia Database
Database of Institut Paoli-Calmettes patients diagnosed with chronic lymphatic leukemia
- Trial name
- NCT02869529
- Testing
- Data collection
- Where
- France
- Volunteers
- 4,200 people
- Sponsor
- Institut Paoli-Calmettes
Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
This phase I trial studies the side effects and best dose of dasatinib in treating patients with solid tumors or lymphomas that are metastatic or cannot be removed by surgery.
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia, Adult Hepatocellular Carcinoma, Adult Nasal Type Extranodal NK/T-Cell Lymphoma
- Trial name
- NCT00608361
- Testing
- Dasatinib, Pharmacological Study
- Where
- 23 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Lymphocytic Leukemia, Chronic
A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status
This multi-center, randomized study compared the efficacy and safety of MabThera (rituximab) in combination with either fludarabine and cyclophosphamide or with chlorambucil in participants with previously untreated B-cell…
- Trial name
- NCT01283386
- Testing
- Chlorambucil, Cyclophosphamide, Fludarabine
- Where
- 8 sites in Russia
- Volunteers
- 26 people
- Sponsor
- Hoffmann-La Roche
Marginal Zone Lymphoma
Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma
The purpose of this research study is to see if loncastuximab tesirine has any benefits at dose levels researchers found acceptable in earlier studies in patients with related forms of immune cell cancers.
- Trial name
- NCT05296070
- Testing
- Loncastuximab tesirine 150 µg/Kg, Loncastuximab tesirine 75µg/Kg
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of Miami
Leukemia
Biomarkers in DNA Samples From Patients With Chronic Lymphocytic Leukemia Previously Treated With Fludarabine-Based Therapy
RATIONALE: Studying samples of DNA in the laboratory from patients who received fludarabine-based treatment may help doctors learn more about the effects of fludarabine on cells.
- Trial name
- NCT01145469
- Testing
- DNA analysis, gene expression analysis, polymorphism analysis
- Volunteers
- 225 people
- Sponsor
- Eastern Cooperative Oncology Group
Large B-cell Lymphoma, Hodgkin Lymphoma
Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
This clinical research study is to learn if CD70.CAR NK cell therapy can help to control early relapsed or primary refractory DLBCL and cHL.
- Trial name
- NCT07164469
- Testing
- Fludarabine, Cyclophosphamide, CD70.CAR NK Cells
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Diffuse Large B-cell Lymphoma, Follicular Lymphoma
A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas
This phase I/Ib study is designed to establish the safety and maximum tolerated dose (MTD, which will also be the recommended phase II dose (RP2D)) of the aurora kinase A inhibitor alisertib when combined with dose-adjusted…
- Conditions
- Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Burkitt Lymphoma
- Trial name
- NCT02700022
- Testing
- Alisertib
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder
Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma
This phase II trial tests how well the combination of epcoritamab and lenalidomide work in treating patients with immunodeficiency-related large B-cell lymphoma that does not respond to treatment (refractory) or that has come…
- Conditions
- Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder, Refractory B-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT06723457
- Testing
- Biospecimen Collection, Computed Tomography, Epcoritamab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Reem Karmali
Multiple Myeloma
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of the study is to characterize safety of JNJ-68284528 and establish the recommended Phase 2 dose (RP2D) (Phase 1b) and to evaluate the efficacy of JNJ-68284528 (Phase 2).
- Trial name
- CARTITUDE-1 (NCT03548207)
- Testing
- JNJ-68284528
- Where
- 21 sites in United States, Japan
- Volunteers
- 126 people
- Sponsor
- Janssen Research & Development, LLC